Sacituzumab govitecan (47) is a trophoblast cell surface antigen 2 (TROP2)-targeting ADC coupled with SN-38, a camptothecin analogue, that has been approved in 2019 for patients with metastatic triple-negative breast cancer (Figure 14) [120]. The gene discussed is TACSTD2; the disease is triple-negative breast carcinoma.